Research graph
References from Rule-derived preoperative inflammatory-lymphocyte recovery phenotype and pathological response in resected osteosarcoma: a retrospective cohort study. Local targets link to admitted publications; unresolved targets remain external evidence.
Translational biology of osteosarcoma
10.1038/nrc3838 · 2014 · External reference
Advancing therapy for osteosarcoma
10.1038/s41571-021-00519-8 · 2021 · External reference
New horizons in the treatment of osteosarcoma
10.1056/nejmra2103423 · 2021 · External reference
Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols
10.1200/jco.2002.20.3.776 · 2002 · External reference
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
10.1016/s1470-2045(16)30214-5 · 2016 · External reference
Osteosarcoma and undifferentiated pleomorphic sarcoma of bone treatment (PDQ) - health professional version
2024 · External reference
Single-cell transcriptomics reveals the complexity of the tumor microenvironment of treatment-naive osteosarcoma
10.3389/fonc.2021.709210 · 2021 · External reference
Ewing sarcoma and osteosarcoma have distinct immune signatures and intercellular communication networks
10.1158/1078-0432.ccr-22-1471 · 2022 · External reference
Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment
10.1038/s41413-023-00246-z · 2023 · External reference
Unlocking the tumor-immune microenvironment in osteosarcoma: insights into the immune landscape and mechanisms
10.3389/fimmu.2024.1394284 · 2024 · External reference
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
10.1016/s1470-2045(17)30624-1 · 2017 · External reference
Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
10.1016/s1470-2045(18)30006-8 · 2018 · External reference
Correlative analyses of the SARC028 trial reveal an association between sarcoma-associated immune infiltrate and response to pembrolizumab
10.1158/1078-0432.ccr-19-1824 · 2020 · External reference
Prognostic performance of pre-treatment NLR and PLR in patients suffering from osteosarcoma
10.1186/s12957-016-0889-2 · 2016 · External reference
Diagnostic and prognostic role of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio, and lymphocyte/monocyte ratio in patients with osteosarcoma
10.52312/jdrs.2021.79775 · 2021 · External reference
Preoperative prognostic nutritional index and systemic immune-inflammation index predict survival outcomes in osteosarcoma: a comparison between young and elderly patients
10.1002/jso.26757 · 2022 · External reference
Predictive value of the systemic immune-inflammation index for cancer-specific survival of osteosarcoma in children
10.3389/fpubh.2022.879523 · 2022 · External reference
Prognostic and clinicopathological value of systemic immune-inflammation index in patients with osteosarcoma: a meta-analysis
10.3389/fimmu.2024.1416068 · 2024 · External reference
The combination of baseline neutrophil to lymphocyte ratio and dynamic changes during treatment can better predict the survival of osteosarcoma patients
10.3389/fonc.2023.1235158 · 2023 · External reference
Immune resilience despite inflammatory stress promotes longevity and favorable health outcomes including resistance to infection
10.1038/s41467-023-38238-6 · 2023 · External reference
The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
10.1136/bmj.39335.541782.ad · 2007 · External reference
Reporting recommendations for tumor marker prognostic studies (REMARK)
10.1093/jnci/dji237 · 2005 · External reference
Immunological aspects of cancer chemotherapy
10.1038/nri2216 · 2008 · External reference
Lymphopenia in cancer patients and its effects on response to immunotherapy: an opportunity for combination with cytokines
10.1186/s40425-019-0549-5 · 2019 · External reference
Tumor-associated macrophages in osteosarcoma: from mechanisms to therapy
10.3390/ijms21155207 · 2020 · External reference
Neutrophil dynamics in the tumor microenvironment
10.1172/jci143759 · 2021 · External reference
The evolving tumor microenvironment: from cancer initiation to metastatic outgrowth
10.1016/j.ccell.2023.02.016 · 2023 · External reference
Neutrophil extracellular traps are associated with poor response to neoadjuvant therapy and poor survival in pediatric osteosarcoma
10.3389/fonc.2025.1472716 · 2025 · External reference
Immune microenvironment in osteosarcoma: components, therapeutic strategies and clinical applications
10.3389/fimmu.2022.907550 · 2022 · External reference
3D tumor cultures for drug resistance and screening development in clinical applications
10.1186/s12943-025-02281-2 · 2025 · External reference
Neuron-tumor crosstalk in cancer: molecular mechanisms and translational advances
10.1186/s12943-026-02715-5 · 2026 · External reference
